Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies

Next Previous
Trial Profile

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Zelenectide pevedotin (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Transitional cell carcinoma; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Acronyms Duravelo-1
  • Sponsors Bicycle Therapeutics

Most Recent Events

  • 21 Apr 2026 According to Bicycle Therapeutics media release, updated data from this study will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29-June 2 in Chicago.
  • 12 Jan 2026 According to Bicycle Therapeutics media release, the company plans to present additional data at a scientific conference and longer-term follow-up Phase 1 Duravelo-1 monotherapy data in the first half of 2026.
  • 01 May 2025 According to Bicycle Therapeutics media release, company will present data from this study as a poster presentation at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top